QD

Quest Diagnostics IncFRA Quest Stock Report

Last reporting period 30 Sep, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

17.04

Large

Exchange

XFRA - Deutsche Boerse AG

QDI.F Stock Analysis

QD

Avoid

Based on Eyestock quantitative analysis, QDI.F`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

51/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-27.4 %

Greatly overvalued

Market cap $B

17.04

Dividend yield

2.41 %

Shares outstanding

111.32 B

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. The company is headquartered in Secaucus, New Jersey and currently employs 40,000 full-time employees. The firm operates through the DIS segment, which provides diagnostic information services to a range of customers, including patients, clinicians, hospitals, independent delivery networks (IDNs), health plans, employers, consumers, and accountable care organizations (ACOs). The company is also engaged in two business operations, Diagnostic Information Services, which develops and delivers diagnostic information services that provide insights to a range of customers, and the Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology business, which offers solutions for healthcare providers. The Company’s services are primarily provided under the Quest Diagnostics brand and also provide services under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.

View Section: Eyestock Rating